PT Prodia Widyahusada Tbk (PRDA) menginformasikan terkait rencana untuk membawa entitas usahanya PT Prodia Diagnostic Line (Proline) untuk masuk pasar modal. Proline disiapkan untuk melaksanakan penawaran umum perdana atau Intial Public Offering (IPO) di Bursa Efek Indonesia (BEI) dalam tempo 2 hingga 3 tahun mendatang.
Category
📺
TVTranscript
00:00PTPRODIA WIDIAHUSADA TBK
00:05PT PRODIA WIDIAHUSADA TBK informs about the plan to bring its business entity, PT PRODIA DIAGNOSTIC LINE, to the stock market.
00:14PRO LINE is prepared to carry out a public offering or initial public offering in the Indonesian stock market in the next 2-3 years.
00:23PT PRODIA WIDIAHUSADA TBK informs about the plan to bring its business entity, PT PRODIA DIAGNOSTIC LINE, to the stock market.
00:35From a number of business units, PRODIA GROUP, PRO LINE will be brought first for IPO.
00:41The management of Perseroan hopes that in a few years' time, PRO LINE will be more developed and ready to become an open company.
00:49PRO LINE is a business unit of PRODIA GROUP that operates in the diagnostic industry in vitro or IVD.
00:55Established since 2010, PRO LINE began production in 2012 with product portfolios such as Regen Chemiaclinic, Urine Strip, Molecular Products, Immunology, etc.
01:07PRODIA WIDIAHUSADA has acquired 39% of PT PRODIA DIAGNOSTIC LINE or PRO LINE shares in July 2024.
01:15In the same year, PRO LINE also built a new factory facility to increase its production capacity.
01:20The plan is that the factory will start operating in April 2025 with increased capacity up to three times the previous factory.
01:27PRODIA GROUP hopes that with the addition of PRO LINE's production capacity, it can support government programs in the health sector, such as free health checks.
01:36The company's management sees that the health industry has opportunities and open potential throughout the year.
01:42One of them is through a new government program that focuses on TDC monitoring and free health checks for 52.2 million Indonesians
01:53as a preventive measure against the potential risk of catastrophic diseases.